英国卫生官员建议Santhera推出新的杜申肌肉衰竭药物, 准备推出NHS. UK health officials recommend Santhera's new Duchenne muscular dystrophy drug, set for NHS rollout.

桑捷拉制药公司药物AGAMREE(vamorolone)收到了英国国家保健和护理英才研究所关于治疗4岁及4岁以上病人的杜切恩肌肉肌肉萎缩的积极建议。 Santhera Pharmaceuticals' drug AGAMREE (vamorolone) has received a positive recommendation from the UK's National Institute for Health and Care Excellence (NICE) for treating Duchenne muscular dystrophy in patients aged 4 and older. 该药物有望在90天内通过英格兰、威尔士和北爱尔兰的国家保健服务机构提供。 The drug is expected to be available through the National Health Service in England, Wales, and Northern Ireland within 90 days. Santhera也在寻求该药物在苏格兰使用的批准。 Santhera is also seeking approval for the drug's use in Scotland.